

IL-15R alpha & IL-15 Protein, Human (Biotinylated, HEK293, His)

Cat. No.:	HY-P77700
Synonyms:	IL-15 R alpha; CD215; IL15RA; IL-15RA; IL-15R-alpha1; Interleukin-15; IL-15; IL15
Species:	Human
Source:	HEK293
Accession:	Q13261 (I31-S108)&P40933 (N49-S162)
Gene ID:	3601&3600
Molecular Weight:	25-28 kDa

PROPERTIES

Biological Activity	Immobilized Human IL-2 R beta&IL-2 R gamma, hFc Tag at 1µg/ml (100µl/well) on the plate. Dose response curve for Biotinylated Human IL-15RA&IL-15, His Tag with the EC ₅₀ of 13.2ng/ml determined by ELISA.
Appearance	Solution.
Formulation	Supplied as a 0.22 µm filtered solution of PBS, pH 7.4.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconstitution	N/A.
Storage & Stability	Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
Shipping	Shipping with dry ice.

DESCRIPTION

Background	<p>IL-15R alpha is expressed on various cell types, including lymphocytes, myeloid cells, nonlymphoid and nonhematopoietic cells^[4]. IL-15 is produced in macrophages and dendritic cells^[1].</p> <p>IL-15R alpha is required for transporting of IL-15 from the endoplasmic reticulum to the cell surface to bind with β (CD122) and γ (CD132) chains on responding lymphocytes^{[4][5]}. When binding with IL-15, the complex increases the in vivo half-life of IL-15 and enhances binding affinity of IL-15 with IL-15Rβ/γ in NK cells and CD8+ T cells. Thus, the signal transmission improves proliferation and antitumor activities of NK cells and CD8+ T cells^[2].</p> <p>IL-15R alpha forms complex with IL-15 and activates the antitumor functions of NK cells and CD8+ T cells. IL-15R alpha/IL-15 complex is a potential immunotherapeutic agent for cancer and viral infection^[1].</p>
------------	---

REFERENCES

[1]. Yin Guo, et al. Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev. 2017 Dec;38:10-21.

-
- [2]. Johan Mj Van den Bergh, et al. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation. *Pharmacol Ther.* 2017 Feb;170:73-79.
- [3]. Spencer W Stonier, et al. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. *Immunol Lett.* 2010 Jan 4;127(2):85-92.
- [4]. Patrick R Burkett, et al. IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory. *Proc Natl Acad Sci U S A.* 2003 Apr 15;100(8):4724-9.
- [5]. Emanuela Romano, et al. Human Langerhans cells use an IL-15R- α /IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. *Blood.* 2012 May 31;119(22):5182-90.
- [6]. Isvoranu G, et al. Immunotherapy in cancer-in vivo study of the anti-tumor activity of the IL-15/IL-15R alfa combination in an experimental model of melanoma[J]. *Farmacia*, 2015, 63: 631-636.
- [7]. Thomas A. Stoklasek, et al. Combined IL-15/IL-15Ra Immunotherapy Maximizes IL-15 Activity In Vivo. *J Immunol* November 1, 2006, 177 (9) 6072-6080;
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA